A clinical core facility for advancing medical research.
Official title: Clinical Core
Funded at Benaroya Research Inst at Virginia Mason · NIH-11295551 · Data updated 2026-11-12
This study is all about creating a helpful team that makes it easier for patients to join exciting new treatments and clinical trials, so they can get better care and access to the latest medical advancements.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | March 29, 2022 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $773,306 |
| NIH project number | 5U19AI167891-04 |
| Project ID | NIH-11295551 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are patients seeking access to new therapies and those involved in ongoing clinical trials at the facility.
✕Less likely to help
Patients not interested in participating in clinical trials or those with conditions not addressed by the core's activities may not receive benefits.
What this research studies
This research focuses on establishing a clinical core that supports various medical investigations by providing essential resources and expertise. It aims to enhance the quality and efficiency of clinical trials and patient care through collaborative efforts. Patients may benefit from improved access to cutting-edge treatments and participation in innovative clinical trials facilitated by this core.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and improved patient outcomes through enhanced clinical trial processes.
How similar studies have gone: While the specific focus of this clinical core is not detailed, similar facilities have historically shown success in improving clinical trial outcomes and patient care.
Where this research is happening
-
Benaroya Research Inst at Virginia Mason
Seattle, United States Active
Researchers
- Principal investigator: Buckner, Jane Hoyt — Benaroya Research Inst at Virginia Mason
- Study coordinator: Buckner, Jane Hoyt
Related research
Other NIH-funded projects on the same topics.
-
T cells and the switch from pre-autoimmunity to autoimmune disease
A study following people at risk for type 1 diabetes and people with Down syndrome to understand how certain T cells may shift toward causing autoimmune disease.
-
Genetic and epigenetic control of T cell function in autoimmune disease
This grant aims to understand how genetic and epigenetic changes affect how T cells behave in autoimmune diseases to find ways to reduce harmful immune responses.
-
Immune Tolerance Network (ITN) for immune tolerance therapies across autoimmune and allergic diseases
A national network runs clinical trials to test new immune-tolerance therapies that could help people with autoimmune and allergic diseases.
-
Immune Tolerance Network for safer, more effective immune therapies
A nationwide network tests new immune therapies to help people with autoimmune diseases, allergies, and transplant patients reach better control of their immune system.
-
Immune tolerance research network for safer transplant and autoimmune therapies
A national effort tests new treatments that make the immune system tolerate transplanted organs and fight autoimmune and allergic diseases more safely.
-
Immune Tolerance Network for allergy, autoimmunity, and transplantation
A large NIH program tests new immune-tolerance therapies to help people with autoimmune diseases, allergies, and transplant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.